BMJ Publishing Group
+4
2051-1426
Continuously
10.9
2024
12678951758
United States
English
YES
Google Scholar
info.jitc@bmj.com
The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. The Journal for ImmunoTherapy of Cancer is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
OJSCloud offers a complete, free setup to get you publishing.
Start Your Free Journal!Scholar9.com is a peer-review platform that hosts journals from across the globe. Please note that we do not own any of the journals hosted on the platform.
Our platform enables journal owners to send articles for peer review to users who have registered via https://scholar9.com/register and have consented to serve as reviewers for multiple journals. Additionally, we offer an indirect manuscript submission system for journals that are claimed and actively managed by their respective owners on Scholar9.com.
For accurate information about the indexing status of journals (in databases such as UGC CARE, Scopus, or Web of Science) and contact details, users must refer to the respective official websites.
Scholar9 is not responsible for indexing claims, manuscript acceptance/rejection, refunds of article processing charges, or any stage of the final publication process. Users are strongly advised to verify all information provided on the platform independently.
Scholar9.com disclaims liability for disputes related to indexing claims, publication decisions, or other journal-specific matters. Users are encouraged to contact the respective journal owners directly for detailed information and clarifications.